03:42 AM EDT, 09/13/2026 (MT Newswires) -- Roche's (RO.SW) collaborator MediLink said the randomized phase III Taishan-302 trial evaluating Tam-Peli in Chinese patients with relapsed small-cell lung cancer achieved its primary endpoint of overall survival, according to a Sunday release. Compared with the standard-of-care topotecan, Tam-Peli lowered the risk of death by 54% and disease progression by 71%, with an objective response rate of 59.1% versus 9.7%. The drug, generically called tambotatug pelitecan, has secured breakthrough therapy designations for relapsed small-cell lung cancer from the US Food and Drug Administration and China's Center of Drug Evaluation. The Swiss-listed pharmaceutical giant has the right to develop, manufacture, and commercialize Tam-Peli outside mainland China, Hong Kong, and Macau.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.